Category Archives: Sacramento

CalPERS Implements Reference-Pricing for Dozens of Drug Classes

At its Nov. 14 board meeting, CalPERS’ Pension and Health Benefits Committee directed its staff to move forward with a Request for Information (RFI) to implement a Full Reference Pricing Program, expanding from their currently proposed three drug class pilot (nasal corticosteroids, thyroid medications, and oral estrogens) to cover up to 70-80 drug classes.

CLSA Urges Governor Jerry Brown to Sign Legislation to Protect Clinical Trials and Patient Access in California

California Life Sciences Association (CLSA) today urged Governor Jerry Brown to sign Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and awaits action by Governor Brown, who has until Sept. 30 to sign or veto the legislation.

New California Data Privacy Law (AB 375) Continues to Pose Challenges for Life Sciences Industry

The California Life Sciences Association (CLSA) joined a coalition, which includes fellow life sciences trade associations, providers, insurers, and a number of other key stakeholders, to address the concerns related to HIPAA preemption and clinical trials data in the recently enacted AB 375, “The California Consumer Privacy Act of 2018” (“Privacy Act”), which will become effective January 1, 2020.

CLSA in BioWorld: Life sciences companies face uncertainty over new California privacy law

California’s new Consumer Privacy Act (AB 375), the toughest data privacy law in the nation, will impose stringent new requirements on the state’s high-profile tech companies in 2020. Its impacts on the life sciences industry, though, remain unclear. CLSA’s State Government Relations team sat down with BioWorld to discuss what the measure means for innovative biomedical companies.